24% mean body weight reduction in a Phase 2 trial. That number has circulated widely in the obesity research world, and for good reason. It's larger than anything previously published for a drug in this class. It is also, at this point, the sum total of what we reliably know about retatrutide in humans.
What retatrutide actually is
Retatrutide is Eli Lilly's next step after tirzepatide. If tirzepatide works by activating two gut hormone receptors (GIP and GLP-1), retatrutide activates three: GIP, GLP-1, and glucagon. That third receptor is the novel piece.
Glucagon is a hormone most people associate with raising blood sugar in an emergency. But glucagon also promotes energy expenditure and drives the liver to burn fat. Adding glucagon receptor activation to the GIP/GLP-1 combination is what researchers believe explains why retatrutide's weight loss numbers exceed tirzepatide's. The glucagon component appears to add an energy-burning effect that the other two pathways don't fully cover on their own.
Retatrutide is not FDA-approved. As of 2026, it is in Phase 3 clinical trials. It is not available through any pharmaceutical channel.
The angle that matters most for women
The weight loss data gets all the attention, but the liver findings are the part I find more interesting for women specifically.
Metabolic dysfunction-associated steatotic liver disease (fatty liver disease linked to metabolic changes rather than alcohol) is underdiagnosed in women and tends to worsen during and after perimenopause, as estrogen levels fall and metabolic health shifts. A parallel Phase 2 analysis published in Nature Medicine found that retatrutide substantially reduced liver fat content, with a meaningful proportion of participants achieving resolution of steatosis at 48 weeks. The glucagon component is thought to contribute through direct effects on fat burning in the liver. For women navigating the metabolic changes of midlife, that's a signal worth watching.
What the research actually shows
One Phase 2 trial. 338 adults with obesity, 48 weeks, published in the New England Journal of Medicine in 2023. At the highest dose (12 mg weekly), mean weight reduction was approximately 24.2%, compared to 2.1% in the placebo group. Weight loss was clearly dose-dependent: more drug, more effect, up to 12 mg. The trial also documented improvements in blood pressure, triglycerides, waist circumference, and blood sugar markers.
The separate liver analysis in Nature Medicine confirmed the fat reduction findings. A 2025 animal study found that retatrutide reduced obesity-driven tumor growth in animal models. That is an early-stage research direction, not a clinical finding, but one that adds to the picture of what glucagon receptor activation might do beyond weight loss.
What we honestly don't know yet
Phase 3 trials are ongoing as of 2026. Results have not been published. That means there is no long-term safety data, no cardiovascular outcomes data, no established dosing protocol for approved pharmaceutical use, and no information about what happens to weight when treatment stops (the tirzepatide data suggests regain is likely, but that's inference, not evidence specific to retatrutide).
The glucagon receptor component (the feature that distinguishes retatrutide from everything that came before it) also introduces monitoring questions that GLP-1-only drugs don't carry. Glucagon raises blood glucose and heart rate. How sustained triple receptor activation plays out in humans over years is genuinely unknown. Researchers studying the compound have flagged this as an area requiring careful attention in the Phase 3 program.
The 24% weight loss number comes from 338 people over 48 weeks. That is a strong Phase 2 result. It is not a Phase 3 result. The sample size, duration, and patient selection in that trial were not designed to detect cardiovascular outcomes, long-term weight maintenance, or safety signals that require larger or longer exposure to appear. Phase 3 data will be the determining evidence.
Research peptide vendors sell retatrutide as a research compound. The product they sell is not the pharmaceutical compound used in clinical trials. It is not manufactured to the same standards, and purity and concentration accuracy vary by source.